Neuromuscular Junction

Key Points

• The neuromuscular junction (NMJ) is the synaptic cleft between a motor neuron axon terminal and a muscle fiber.
• Acetylcholine (ACh) is released from the presynaptic terminal and binds ACh receptors on the motor end plate.
• ACh binding triggers muscle fiber depolarization → contraction.
• NMJ dysfunction underlies myasthenia gravis, Lambert-Eaton syndrome, and neuromuscular blocking drug effects.

Pathophysiology

Normal NMJ function requires a motor-neuron action potential, presynaptic acetylcholine release, receptor binding at the motor end plate, and rapid signal termination by acetylcholinesterase so contraction remains controlled. Because skeletal muscle relies on this neural signaling sequence, NMJ disruption can produce immediate weakness and fatigability.

In myasthenia gravis, autoantibodies target and destroy postsynaptic ACh receptors, reducing available binding sites. This produces fatigable muscle weakness that worsens with activity and improves with rest. In Lambert-Eaton syndrome, presynaptic calcium channels are targeted instead.

Related Concepts

• myasthenia-gravis - Autoimmune disease targeting ACh receptors at the NMJ.
• neuromuscular-diagnostic-testing - Testing methods to evaluate NMJ and motor pathway function.
• nursing-care-priorities-for-neuromuscular-impairment - Assessment and intervention priorities.